Raising awareness to fight Renal Medullary Carcinoma and other rare renal cancers
Founded in 2020, The Ricky Casey Trust is a charity that aims to further the understanding and expand the knowledge of Renal Medullary Carcinoma (RMC) and rare renal cancers. We also provide support to those who are suffering from these diseases, and their families.
A rare cancer that has been left behind
Renal Medullary Carcinoma (RMC) is a rare, aggressive form of kidney cancer, almost exclusively associated with people who carry the sickle-cell trait, have sickle-cell disease, or another sickle-cell haemoglobinopathy of the red blood cells.
Cancer patients are living longer thanks to clinical trials — but rare cancers like RMC are being left behind. Ricky was denied access to a drug because there were no trials and not enough data. We want to change that.
Knowledge, research & support
The Trust seeks to advance the knowledge, education and research into rare renal cancers in the UK, particularly the RMC subtype. We aim to raise funds to improve awareness among the public and healthcare professionals, fund vital research, and provide equipment and treatment to relieve sickness and preserve health.
We are proud to work alongside Sickle Cell Care Manchester, run by individuals whose lives have been affected by sickle cell disease, to raise awareness together.
Read our full missionHelp us reach £300,000
Setting up the first UK clinical trial for RMC needs around £500k. Every donation takes us closer to making it a reality.
Cumulative total raised since 2020.
Get to know the Trust
Ricky's Story
Learn about Ricky's life, diagnosis and treatment as he battled against Renal Medullary Carcinoma — told by his wife, Nicola.
Read moreOur Mission
Find out more about the Trust's aims and objectives, and meet the trustees and patrons behind our work.
Read moreMedical Information
Tom Waddell, Consultant in Medical Oncology at The Christie, explains RMC and rare renal cancers in detail.
Read moreCan you help us?
We rely on your donations to continue our important work, and we welcome any offers of your valuable time.
If you are a medical professional and feel that you can help us — or that we can help you — with research into rare renal cancers, we would love to hear from you.